{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:24:47Z","timestamp":1787293487784,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cjca.2026.07.364","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:05:13Z","timestamp":1784934313000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dexrazoxane for Cardioprotection During Anthracycline Therapy: A Systematic Review and Meta-analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4088-4912","authenticated-orcid":false,"given":"Guy","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyan","family":"Heybati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Yonkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi Kang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harikrishnaa Ba","family":"Ramaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Chelf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W.","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7583-3355","authenticated-orcid":false,"given":"Jordan C.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.07.364_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: state of the art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2026.07.364_bib3","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: Where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.07.364_bib4","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.07.364_bib6","year":"2014","journal-title":"US Food and Drug Administration"},{"key":"10.1016\/j.cjca.2026.07.364_bib7","series-title":"European Medicines Agency (EMA)","year":"2023"},{"key":"10.1016\/j.cjca.2026.07.364_bib8","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1111\/bph.70085","article-title":"Dexrazoxane protects against doxorubicin-induced cardiotoxicity in susceptible human living myocardial slices: a proof-of-concept study","volume":"182","author":"van der Geest","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjca.2026.07.364_bib9","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II\u03b2 mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cjca.2026.07.364_bib10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/CAD.0000000000000514","article-title":"Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival","volume":"28","author":"Tahover","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cjca.2026.07.364_bib12","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2026.07.364_bib13","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2026.07.364_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib15","series-title":"WHO handbook for reporting results of cancer treatment","year":"1979"},{"key":"10.1016\/j.cjca.2026.07.364_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5306\/wjco.v11.i2.53","article-title":"Objective response rate assessment in oncology: current situation and future expectations","volume":"11","author":"Aykan","year":"2020","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib17","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2026.07.364_bib18","article-title":"ROBINS-I: a tool for assessing risk of bias in nonrandomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2026.07.364_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.cjca.2026.07.364_bib20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/sim.791","article-title":"On tests of the overall treatment effect in meta-analysis with normally distributed responses","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2026.07.364_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cjca.2026.07.364_bib22","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2026.07.364_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.cjca.2026.07.364_bib24","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival end points","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2026.07.364_bib25","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2026.07.364_bib26","series-title":"Cochrane handbook for systematic reviews of interventions (v6.2)","year":"2021"},{"key":"10.1016\/j.cjca.2026.07.364_bib27","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary end points","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2026.07.364_bib28","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jclinepi.2005.01.006","article-title":"In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias","volume":"58","author":"Terrin","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cjca.2026.07.364_bib29","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2026.07.364_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the Core GRADE approach","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2026.07.364_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cjca.2026.07.364_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083866","article-title":"Core GRADE 6: presenting the evidence in summary of findings tables","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2026.07.364_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cjca.2026.07.364_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cjca.2026.07.364_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000501195","article-title":"Use of cardioprotective dexrazoxane is associated with increased myelotoxicity in anthracycline-treated soft-tissue sarcoma patients","volume":"64","author":"Spalato Ceruso","year":"2019","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cjca.2026.07.364_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf370","article-title":"Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy","volume":"30","author":"Jang","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.cjca.2026.07.364_bib37","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/1078-0432.CCR-20-4592","article-title":"Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial","volume":"27","author":"Jones","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cjca.2026.07.364_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14705","article-title":"Evaluation of dexrazoxane effect on preventing acute cardiac arrhythmia in patients with breast cancer treated with neoadjuvant\/adjuvant anthracycline-based chemotherapy","volume":"75","author":"Kaplan","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cjca.2026.07.364_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4048\/jbc.2017.20.1.82","article-title":"Cardioprotective effect of dexrazoxane in patients with HER2-positive breast cancer who receive anthracycline based adjuvant chemotherapy followed by trastuzumab","volume":"20","author":"Kim","year":"2017","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.cjca.2026.07.364_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO.1998.16.1.86","article-title":"Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas","volume":"16","author":"Lopez","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1621409","article-title":"Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity","volume":"15","author":"Neiman","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM198809223191203","article-title":"Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer","volume":"319","author":"Speyer","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.07.364_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.1992.10.1.117","article-title":"ICRF-187 permits longer treatment with doxorubicin in women with breast cancer","volume":"10","author":"Speyer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005228","article-title":"Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjca.2026.07.364_bib46","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/MAJ.0000000000000432","article-title":"Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity","volume":"349","author":"Sun","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cjca.2026.07.364_bib47","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.1996.14.12.3112","article-title":"Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer","volume":"14","author":"Venturini","year":"1996","journal-title":"J Clin Oncol"},{"issue":"921","key":"10.1016\/j.cjca.2026.07.364_bib48","first-page":"15","article-title":"Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment","volume":"149","author":"Vici","year":"1998","journal-title":"Clin Ter"},{"key":"10.1016\/j.cjca.2026.07.364_bib49","first-page":"771","article-title":"Preventive effects of dexrazoxane on anthracycline-induced cardiac toxicity in post-surgery breast cancer patients","volume":"9","author":"Zhao","year":"2019","journal-title":"Antitumor Pharm"},{"key":"10.1016\/j.cjca.2026.07.364_bib50","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.cjca.2026.07.364_bib51","first-page":"296","article-title":"Advanced small cell lung cancer treated with CAV (cyclophosphamide+adriamycin+vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICRF-187, ZINECARD)","volume":"11","author":"Feldmann","year":"1992","journal-title":"Proc Am So Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib52","first-page":"348","article-title":"Clinical study on anthracycline cardiotoxicity reduction by dexrazoxane combined with Shen Mai injection","volume":"39","author":"Zhuang","year":"2012","journal-title":"Chin J Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jcpt.12124","article-title":"Incidence and risk-factors of CHOP\/R-CHOP\u2013related cardiotoxicity in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"39","author":"Limat","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cjca.2026.07.364_bib55","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/annonc\/mdw671","article-title":"Interventions for preventing cardiomyopathy due to anthracyclines: a bayesian network meta-analysis","volume":"28","author":"Abdel-Qadir","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2022.03.024","article-title":"Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis","volume":"169","author":"Sayed","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cjca.2026.07.364_bib57","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.cjca.2026.07.364_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.23.01779","article-title":"Cardiac dysfunction among breast cancer survivors: role of cardiotoxic therapy and cardiovascular risk factors","volume":"43","author":"Bostany","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib59","doi-asserted-by":"crossref","first-page":"e926","DOI":"10.1161\/CIR.0000000000001308","article-title":"Cardiovascular toxicity in patients treated for childhood cancer: a scientific statement from the American Heart Association","volume":"151","author":"Ryan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.07.364_bib60","doi-asserted-by":"crossref","DOI":"10.1590\/1806-9282.20250322","article-title":"Beta-blockers for preventing anthracycline-induced cardiotoxicity: a systematic review with network meta-analysis","volume":"71","author":"Pacheco","year":"2025","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.cjca.2026.07.364_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8367444","article-title":"Beta-blockers for primary prevention of anthracycline-induced cardiac toxicity: an updated meta-analysis of randomized clinical trials","volume":"2022","author":"Attar","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cjca.2026.07.364_bib62","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaccao.2024.02.004","article-title":"Dexrazoxane to prevent cardiotoxicity in adults treated with anthracyclines: JACC: cardiooncology controversies in cardio-oncology","volume":"6","author":"Upshaw","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cjca.2026.07.364_bib63","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/1471-2407-14-842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cjca.2026.07.364_bib64","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/TCRM.S3694","article-title":"Anthracycline extravasation injuries: management with dexrazoxane","volume":"5","author":"Jordan","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cjca.2026.07.364_bib65","first-page":"2221","article-title":"Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia","volume":"28","author":"Shokane","year":"2023","journal-title":"Health SA"},{"key":"10.1016\/j.cjca.2026.07.364_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-003-0498-7","article-title":"The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review","volume":"130","author":"Swain","year":"2004","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26010457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26010457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:46:02Z","timestamp":1787291162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26010457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":64,"alternative-id":["S0828282X26010457"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.07.364","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dexrazoxane for Cardioprotection During Anthracycline Therapy: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.07.364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}